GE
AGIO icon

General Electric’s Agios Pharmaceuticals AGIO Stock Holding History

General Electric’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-164,461
Closed -$7.54M – 218
2014
Q2 		$7.54M Buy
+164,461
New +$6.7M 0.03% 144

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

General Electric's AGIO Position: Q3 2014 in Review

General Electric sold out of Agios Pharmaceuticals (AGIO) in Q3 2014, closing a stake of 164,461 shares — an estimated $7.54M sold.

General Electric first reported a position in AGIO in Q2 2014 and held it in 1 quarter. The position peaked at $7.54M in Q2 2014. 120 funds tracked by Wall St. Rank hold AGIO as of Q3 2014.

  • General Electric reported no remaining Agios Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • General Electric sold 164,461 Agios Pharmaceuticals shares in Q3 2014, an estimated $7.54M.
  • General Electric first reported a position in Agios Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • General Electric's Agios Pharmaceuticals position peaked at $7.54M in Q2 2014.
  • 120 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2014.

Based on General Electric's 13F filing for Q3 2014, filed 14 Nov 2014.